Navigation Links
MoxDuo(TM) IR Demonstrates Fewer Side Effects Than Percocet(R)
Date:8/26/2009

uce Nicholson, a leading pain physician in the US, commented on these results: "The concept of combining morphine and oxycodone makes sense based on the clinical data generated to date, and has benefited my patients in managing their acute and chronic pain needs. Results of this study reinforce that the clinical advantages of MoxDuo(TM) IR have the potential to change the traditional methods of treating moderate to severe pain by providing better pain relief without many of the debilitating side effects seen with traditional opioid drugs."

Based on the Company's July 2008 FDA meeting, final Phase 3 studies for MoxDuo(TM) IR will include: (1) a "double-blind combination rule" trial in patients experiencing post-surgical (bunionectomy) pain that compares MoxDuo(TM) IR against morphine alone and oxycodone alone and (2) a double-blind controlled study to evaluate the effectiveness of MoxDuo(TM) IR in patients following total knee replacement. No additional pharmacology, toxicology or long-term clinical safety studies will be required for regulatory submission and market approval.

Forward Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgment of QRxPharma as of the date of this release. These forward-looking statements are not guarantees for future performance. Actual results could differ materially from those currently anticipated due to a number of factors including risks relating to the stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialisation of the Company's proposed products.

About QRxPharma

QRxPharma (ASX: QRX) and (OTCQX: QRXPY) is a clinical-stage specialty pharmaceutical company focused on the developme
'/>"/>

SOURCE QRxPharma Limited
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients
2. Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharmas Product Class
3. Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases
4. Thiarabine Demonstrates a Reduction of Both Inflammatory and Erosive Disease Parameters in Rheumatoid Arthritis
5. Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia
6. Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
7. Study Demonstrates Efficacy of Pitavastatin in Elderly Patients
8. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
9. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
10. Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
11. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 24, 2013  Auxilium Pharmaceuticals, Inc. (Nasdaq: ... in the Deutsche Bank Health Care Conference to be ... Mr. Adrian Adams , Chief Executive ... of the Company and its product pipeline at 12:00 ... (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ) The presentation ...
(Date:5/24/2013)... and BOSTON , May 24, 2013 ... and development company, is pleased to announce that it has engaged ... augment the Company,s business development capabilities in Japan ... than 15 years of experience in business development, licensing and alliance ... Inc., Roche Pharma ( Japan ), Nippon Roche and ...
(Date:5/23/2013)... 2013 Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... President and Chief Executive Officer of Neurocrine Biosciences, will be ... Health Care Conference in Boston.   The live ... Eastern Time / 8:20 a.m. Pacific Time.  The presentation will ... at http://www.neurocrine.com . If you are ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 4Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 2
... (Nasdaq: REGN ) will webcast its presentation at the ... Tuesday, May 10, 2011 at 9:20 a.m. Pacific Time (12:20 ... Company,s web site, www.regeneron.com , on the Investor Relations ... after the live webcast through May 27, 2011.   ...
... MISSISSAUGA, Ontario, May 2, 2011 Valeant Pharmaceuticals International, Inc. ... Pharmaceutical Industries Ltd. (NASDAQ: TEVA ) and Cephalon, ... to be acquired by Teva.  In response to the news, ... believe that this announcement is positive news for Cephalon stockholders ...
Cached Medicine Technology:Valeant Pharmaceuticals Congratulates Teva and Cephalon on Their Transaction 2
(Date:5/24/2013)... 2013 myMEDholiday.com, a popular medical tourism ... in five important medical travel destinations in Asia, has ... to ensure a safe and successful trip for ... manual offers tips on cost-savings, how to find the ... and a wealth other essential advice. , A top-level ...
(Date:5/24/2013)... 2013 Range Kleen Mfg. strives to “TCOTC.” ... Customer, from the President's desk to the Shipping Dock.” We ... integrity, and having passion while creating excellence and quality being ... company to do the right thing and what better way ... affected by devastation. , Throughout the year Range Kleen donates ...
(Date:5/24/2013)... This week is National EMS Week, which recognizes ... the best emergency care and to improve health communications ... to educate the public that all can play a ... first link, and a very important one. According to ... cardiac arrest can triple a victim’s chance of survival. ...
(Date:5/24/2013)... 24 (HealthDay News) -- Patients hospitalized for heart failure ... admitted on Mondays or in the morning, a new ... are highest among heart failure patients admitted in January, ... are scheduled to present their findings Saturday in Portugal ... of the European Society of Cardiology. "The ...
(Date:5/24/2013)... 2013 KC and Monica Craichy, Founders of ... FreeRide836. Their oldest sons, Kyle and Austin Craichy, will be ... and several professional kiteboarders. , KC Craichy said he is ... miraculously come together such that virtually everyone who planned to ... 20 kite boarders will meet at Matheson Hammock Park and ...
Breaking Medicine News(10 mins):Health News:myMEDholiday.com Introduces International Patient Guide to Assist People Planning Treatment Abroad 2Health News:Range Kleen Partners with Berndes in Red Cross Promotion: Taking Care of Oklahoma 2Health News:Acadian Medics Reunite with Miracle Baby 2Health News:Monday Best Time for Hospitalization With Heart Failure, Study Says 2Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 2Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 3
... ... entire chapter dedicated to this persistent, unpleasant side effect of general anesthesia -- postoperative ... anesthesia as a non-PONV technique in the latest Miller,s ,Anesthesia, top anesthesia textbook. ... Corona del Mar, ...
... , CAPE TOWN, South Africa, June 9 The ... growth over the next five years, driven by an ... procedures. However, price sensitivity and competition in the market ... to purchase imaging systems and the financial constraints faced ...
... 8 Brookdale Senior Living Inc. (NYSE: BKD ... disclosed public offering of 13,953,489 shares of common stock, at ... underwriters in the offering exercised in full their option to ... at the public offering price, resulting in net proceeds to ...
... , , Editorial note: Call (202) 303-5551 to speak with ... WASHINGTON, June 8 The upcoming transition ... on the disaster preparedness plans of many people who have relied ... disaster, and the American Red Cross urges you to update your ...
... Donor Mass , , WASHINGTON, June 8 ... ceremony to honor the 54 men and women who donated ... The yearly Donor Mass celebrated on Georgetown,s campus, was attended ... who chose to make this unique gift in order to ...
... especially strong among those in their 20s, study finds, , ... in colorectal cancer rates in the United States in the ... actually on the upswing among people younger than 50. , ... -- now running annually at 2.8 percent and 2.2 percent ...
Cached Medicine News:Health News:Anesthesia Can Make Patients Vomit After Cosmetic Surgery - World's Top Expert Says PK Anesthesia Is Better 2Health News:Anesthesia Can Make Patients Vomit After Cosmetic Surgery - World's Top Expert Says PK Anesthesia Is Better 3Health News:Frost & Sullivan: Replacement of Old Equipment Boosts Kenyan Medical Imaging Industry 2Health News:Frost & Sullivan: Replacement of Old Equipment Boosts Kenyan Medical Imaging Industry 3Health News:Frost & Sullivan: Replacement of Old Equipment Boosts Kenyan Medical Imaging Industry 4Health News:Brookdale Announces Completion of Follow-On Offering 2Health News:Brookdale Announces Completion of Follow-On Offering 3Health News:Brookdale Announces Completion of Follow-On Offering 4Health News:Brookdale Announces Completion of Follow-On Offering 5Health News:Digital TV Transition Coming Soon; Update Preparedness Plans 2Health News:Digital TV Transition Coming Soon; Update Preparedness Plans 3Health News:A Sacred Celebration: Georgetown School of Medicine Honors Donors 2Health News:Colorectal Cancer Rates Rising for Under 50 Set 2Health News:Colorectal Cancer Rates Rising for Under 50 Set 3
Inquire...
... a premium agarose used for isolating DNA ... produces clear sharp bands, with no smearing ... UltraClean Forensic Agarose is tested and certified ... activity and DNA contamination. Meets ...
... 1000 is specifically formulated for high resolution ... <1000 bp. This standard melting temperature agarose ... as 10 bp difference in size. ... gel structure for better handling and improved ...
Excellent multi purpose agarose Nuclease-free, Gel point (1.5%): 36 1.5 C, EEO: 0.05-0.13 Gel strength (1%): > 1200 g/cm 2 ....
Medicine Products: